Initial target indications are in fertility and pregnancy, where the company seeks to offer the world’s first drug-device combo product to help prevent miscarriages and for IVF luteal support.
In time, this vaginal drug-delivery platform can be used to deliver a wide range of existing and upcoming vaginal therapeutics, including infertility, miscarriage, endometriosis, bacterial vaginosis and cervical cancer.
Sector: MedTech
Raise: £1.5m EIS eligible
PACP Partner Contact: Sharon O’Connor
Latest News
-
May Update: Recent Good News Round Up
We’re delighted to give an update of recent good news from the Prime Advantage team… PACP REPRESENTED AT HOUSE OF COMMONS SME & ENTREPRENEURSHIP SUMMIT Our Managing Partner, Greg Tufnell, recently attended a select gathering at the House of Commons, representing PACP at an event focussed on SMEs, entrepreneurs and the future of UK Professional …
-
Investment Opportunities with Female Founders: Environmental Sustainability
Thanks to all who joined us last week for our Female Founders: Environmental Sustainability Virtual Pitch Event hosted by our Consumer Partner Pippa Bazalgette. We’re delighted to share details of the 3 pitching businesses with links to request the investor decks, watch the pitch videos and an introduction to the founders. SAVE THE DATE for …
Continue reading “Investment Opportunities with Female Founders: Environmental Sustainability”
-
April Focus: Environmental Sustainability & Female Founders
Internet Retailing recently revealed that Vinted is now the third largest fashion retailer in the UK, after Primark and Next, giving further evidence that Environmental Sustainability is now considered mainstream. Being sustainable is no longer a “nice to have” addition to a product or service, it’s now a major decision driver. The Drapers Sustainability and …
Continue reading “April Focus: Environmental Sustainability & Female Founders”